基于WHO药物警戒数据库识别与肺动脉高压相关的新药
本研究利用WHO药物警戒数据库VigiBase,通过贝叶斯神经网络方法对2184例特发性肺动脉高压病例进行不成比例分析,生成93个信号,经专家按WHO因果关系分类评估,发现4种新的蛋白激酶抑制剂、1种血管生成抑制剂及多种化疗药和免疫抑制剂可能与PAH相关。
要点
- 识别出4种新的蛋白激酶抑制剂(拉帕替尼、劳拉替尼、帕纳替尼、鲁索替尼)与PAH信号。
- 贝伐珠单抗及多种化疗药(依托泊苷、曲妥珠单抗等)和免疫抑制剂(来氟米特等)显示PAH信号。
- 93个信号中25个很可能、15个可能、28个可能、25个不太可能,需进一步验证。
核心结论
- 基于药物警戒数据库的不成比例分析生成了93个与特发性PAH相关的药物信号,其中部分为新发现。
- 这些信号在考虑药物药理活性和病例特征后被认为是合理的药物不良反应,但需确证性研究。
研究设计与样本
- 研究使用WHO全球药物警戒数据库VigiBase,采用贝叶斯神经网络方法进行不成比例分析。
- 纳入2184例特发性PAH病例,生成93个不成比例信号,由PAH、药物警戒和血管药理学专家独立审查并按WHO因果关系分类排序。
主要发现
- 93个信号中,25个被认为很可能,15个可能,28个可能,25个不太可能。
- 新识别出4种蛋白激酶抑制剂(拉帕替尼、劳拉替尼、帕纳替尼、鲁索替尼)和1种血管生成抑制剂(贝伐珠单抗)与PAH信号。
- 还发现多种化疗药(依托泊苷、曲妥珠单抗)、抗代谢药(阿糖胞苷、氟达拉滨、氟尿嘧啶、吉西他滨)和免疫抑制剂(来氟米特、沙利度胺、环孢素)的信号。
临床怎么用
- 临床医生面对发生PAH的患者时,可考虑药物性病因,尤其是使用上述信号药物的患者。
- 这些信号有助于提示临床对相关药物引起PAH的可能性保持警惕,但需进一步确证研究。
局限性
- 研究为基于自发报告数据库的不成比例分析,存在报告偏倚和混杂因素,不能确立因果关系。
- 需要确证性研究来验证这些信号。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Since the 1960s, several drugs have been linked to the onset or aggravation of pulmonary arterial hypertension (PAH): dasatinib, some amphetamine-like appetite suppressants (aminorex, fenfluramine, dexfenfluramine, benfluorex) and recreational drugs (methamphetamine). Moreover, in numerous cases, the implication of other drugs with PAH have been suggested, but the precise identification of iatrogenic aetiologies of PAH is challenging given the scarcity of this disease and the potential long latency period between drug intake and PAH onset. In this context, we used the World Health Organization's pharmacovigilance database, VigiBase, to generate new hypotheses about drug associated PAH. METHODS: We used VigiBase, the largest pharmacovigilance database worldwide to generate disproportionality signals through the Bayesian neural network method. All disproportionality signals were further independently reviewed by experts in pulmonary arterial hypertension, pharmacovigilance and vascular pharmacology and their plausibility ranked according to World Health Organization causality categories. RESULTS: We included 2184 idiopathic PAH cases, yielding a total of 93 disproportionality signals. Among them, 25 signals were considered very likely, 15 probable, 28 possible and 25 unlikely. Notably, we identified 4 new protein kinases inhibitors (lapatinib, lorlatinib, ponatinib and ruxolitinib), 1 angiogenesis inhibitor (bevacizumab), and several chemotherapeutics (etoposide, trastuzumab), antimetabolites (cytarabine, fludarabine, fluorouracil, gemcitabine) and immunosuppressants (leflunomide, thalidomide, ciclosporin). CONCLUSION: Such signals represent plausible adverse drug reactions considering the knowledge of iatrogenic PAH, the drugs' biological and pharmacological activity and the characteristics of the reported case. Although confirmatory studies need to be performed, the signals identified may help clinicians envisage an iatrogenic aetiology when faced with a patient who develops PAH.
引用
- Hlavaty A, Roustit M, Montani D, et al. Identifying new drugs associated with pulmonary arterial hypertension: A WHO pharmacovigilance database disproportionality analysis. Br J Clin Pharmacol. 2022. PMID: 35679331. doi:10.1111/bcp.15436
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。